SCHEMBL23988435

SCHEMBL23988435

Cc1cnc(CC(=O)c2nc3ccccc3[nH]2)c(C)c1OCC(F)(F)F

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SARM1 Q6SZW1 2/20 0.64
KMT2A Q03164 6/20 0.46
WDR5 P61964 3/20 0.46
MAPT P10636 6/20 0.43
NPC1 O15118 5/20 0.43
RAB9A P51151 5/20 0.43
ALDH1A1 P00352 4/20 0.43
CYP1A2 P05177 3/20 0.43
HSD17B10 Q99714 3/20 0.43
KDM4E B2RXH2 3/20 0.43
ENGASE Q8NFI3 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
ATP1A1 P05023 2/20 0.43
ATP1B1 P05026 2/20 0.43
ATP1A3 P13637 2/20 0.43
ATP1B2 P14415 2/20 0.43
ATP4A P20648 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24571890 0.88 KMT2A (0.49) SARM1KMT2AWDR5MAPTNPC1
SCHEMBL23988581 0.87 SARM1 (0.49) SARM1KMT2AWDR5MAPTNPC1
SCHEMBL23988510 0.86 KMT2A (0.61) SARM1KMT2AWDR5MAPTNPC1
SCHEMBL23988594 0.86 SARM1 (0.48) SARM1KMT2AWDR5MAPTALDH1A1
SCHEMBL23988370 0.85 SARM1 (0.47) SARM1KMT2AWDR5MAPTALDH1A1
SCHEMBL23988584 0.85 SARM1 (0.47) SARM1KMT2AWDR5MAPTNPC1
SCHEMBL13607834 0.83 MAPT (0.63) SARM1KMT2AWDR5MAPTNPC1
SCHEMBL23988449 0.80 SARM1 (0.61) SARM1KMT2AWDR5MAPTNPC1
SCHEMBL23988414 0.78 SARM1 (0.64) SARM1KMT2AWDR5MAPTNPC1
SCHEMBL23988407 0.78 SARM1 (0.61) SARM1KMT2AWDR5MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220202796-A1 CXCL10 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-06-30 US disclosed
US-20210338650-A1 CXCL10 Inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220202796-A1 CXCL10 Inhibitors CXCL10, CCL5, CCL11 SARM1 3076/4885KMT2A 3380/4885WDR5 3395/4885
US-20210338650-A1 CXCL10 Inhibitors CXCL10, CCL5, CCL11 SARM1 3076/4885KMT2A 3380/4885WDR5 3395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.